Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the ...

Zunveyl (benzgalantamine) is now available for the treatment of mild to moderate dementia of the Alzheimer type in adults.

Northwestern Health Sciences University (NWHSU), a leading health sciences university, announced the creation of a major endowed scholarship by The Joint Corp., the nation's largest franchisor of ...

Wellen Park, the #6 top-selling master-planned community in the US, is expanding outdoor recreation this year with the addition of three new parks and approximately 10 miles of nature trails. Located ...

Findings showed no significant reduction in cognitive or functional decline with simufilam when compared with placebo. Topline results were announced from a phase 3 trial evaluating simufilam, an ...

Credit: Hugel. Letybo, an acetylcholine release inhibitor and a neuromuscular blocking agent, was approved in March 2024 based on data from three phase 3 trials. Letybo should be administered no ...

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory ...

The study aims to measure changes in symptoms and disease activity scores as well as treatment-emergent adverse events. A Chinese study is recruiting patients with relapsed or refractory autoimmune ...

Everyone with Pompe disease is diagnosed at different times in life, so the level of muscle weakness differs from person to person. My daily challenges might be different from those of the next person ...

Short-term memory loss can be a sign of early-stage Alzheimer's disease. It can manifest as difficulty creating new memories or problems retrieving them. For example, someone with early Alzheimer's ...